Background

 “Tropical diseases — some of them never before seen in the United States — are marching northward as climate change lets mosquitoes and ticks expand their ranges.” Donald G. McNeil Jr.,  The New York Times (Jan 4, 2016).

The general belief that tropical diseases are a problem affecting mainly very poor people in developing countries has started to change. The emergence and reemergence of formerly tropical and vector-borne bacterial, viral and parasitic infections in heavily populated areas around the globe are becoming more frequent.  Development of vaccines to prevent and/or treat those diseases must start to be considered a high priority.  The need for greater attention to the control of diseases like leishmaniasis which are currently heavily dependent on chemotherapy is the focus of ZingyGen’s research efforts. Current treatment strategies that employ drugs associated with severe toxic side effects and which result in increasing parasite drug resistance must be replaced before the spread of these infectious disease agents become a major worldwide medical dilemma. 

 

Objective

The ZingyGen platform takes advantage of the experience of the scientific staff who have studied how the parasite successfully controls the immunoregulatory mechanisms that suppress specific cell responses in human hosts. The goal of ZingyGen is to apply this knowledge to design novel vaccines and therapies focused on the control of inflammatory acute and chronic diseases.